Previous 10 | Next 10 |
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Jefferies Healthcare Conference taking place June 8-10 in New York, New ...
Everyone seems to have a strategy when it comes to cheap stocks to buy. Maybe it’s finding the direction of the wind or seeing if a solar eclipse is coming. All joking aside, there are some pretty unique “strategies” that traders use to build their watch list. On a more...
Results demonstrate that reSET-O ® , the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of opioid use disorder (OUD), reached patients across a broad range of geographies, from urban to rural 1 Results suggest PDTs may enable broade...
Fulfilment rates are growing relative to last quarter, and so are prescriptions. Government traction is becoming more evident as states mandate coverage of Pear products for all resident Medicaid members, and payment rates should rise on account of that. As a digital company, they...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it will host an inaugural virtual Investor Day on June 6, 2022, at 10:00 a.m. – 12:30 p.m. ET. P...
Pear Therapeutics, Inc. (PEAR) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of Corporate Communications Ronan O'Brien - General Counsel and Chief Compliance Officer Corey McCann - President and Chief Executive Officer Chris Guiff...
108% quarter-over-quarter revenue growth to $2.7 million >9,200 total prescriptions in the first quarter for Pear’s three FDA-authorized products Expanded patient access with state payors in Michigan and Oklahoma CMS issued new HCPCS code Pe...
Pear Therapeutics (NASDAQ:PEAR) is scheduled to announce Q1 earnings results on Monday, May 16th, after market close. The consensus EPS Estimate is -$0.23 and the consensus Revenue Estimate is $2.4M Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. Revenue esti...
Pear’s second telehealth offering for reSET-O® is with QuickMD, a telemedicine platform providing consultations and urgent care Pear is working with QuickMD to assist eligible patients in their recovery from opioid use disorder Pear Therapeutics, In...